Merck & Co MRK.N has agreed to acquire Prometheus Biosciences Inc RXDX.O for about $10.8 billion to bolster the company’s presence in immunology, the companies said on Sunday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
